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Introduction 61 The clinical symptoms of Plasmodium falciparum malaria are attributed to the blood stage of coated with synthetic peptide P1, but none or only marginal binding to beads coated with synthetic 232 peptides P2 and P3 (Fig. 5a ). Known 14-3-3 binding peptides AA (ARSHpSYPA) and RA 233 (RLYHpSLPA) based on canonical 14-3-3 binding motifs (15) also showed binding to Pf14-3-3I-GST 234 similar to peptide P1 in control experiments (Fig. 5a ).
236
Phosphopeptide from PfPKAr specifically inhibits interaction between Pf14-3-3I and PfPKAr in 237 merozoites. Given that phosphopeptide P1 can bind to Pf14-3-3I in vitro, we next tested if P1 can 238 inhibit binding of Pf14-3-3I to PfPKAr to inhibit multi-protein complex formation in merozoites. We 239 first confirmed that peptide P1 can enter P. falciparum merozoites. Peptide P1 tagged with fluorophore 240 fluorescein isothiocynate (FITC) was incubated with merozoites and tested for uptake by detecting the 241 internalized peptide by fluorimetry ( Fig. S5 ). Uptake of P1-FITC was observed at concentrations above 242 25 µM ( Fig. S5 ). Merozoites were incubated with peptides P1, P2 and P3 at 100 µM. Subsequently, 243 merozoite lysates were used for IP with anti-Pf14-3-3I antisera. PfPKAr and PfCDPK1 were detected 244 in the IPs by western blotting. Phosphorylated peptide P1 inhibited the interaction between Pf14-3-3I 245 and PfPKAr, while peptides P2 and P3 had no effect (Fig 5b) . Interestingly, none of the peptides (P1, 246 P2, and P3) had any effect on the interaction between Pf14-3-3I and PfCDPK1. The small-molecule 247 inhibitor BV02 that blocks binding of mammalian 14-3-3 to its phosphorylated target proteins (15,16), 248 inhibited binding of both PfPKAr and PfCDPK1 with Pf14-3-3I ( Fig. 5c ).
250
Blocking Pf14-3-3I interactions inhibits merozoite invasion of RBCs and microneme secretion. 251 We observed above that a low K + environment triggered Pf14-3-3I mediated formation of a high-252 molecular-weight multi-protein complex composed of PfCDPK1, PfPKAr, and PKAc, all of which are 253 involved in RBC invasion (4, 5, 17). Next, we investigated if disruption of Pf14-3-3I-mediated binding of PfPKAr and PfCDPK1 can inhibit RBC invasion. P. falciparum merozoites isolated in low K + buffer 255 were treated with increasing concentrations of peptides P1, P2 and P3 (10 µM, 50 µM or 100 µM) and 256 BV02 (0.5 µM, 1 µM, 1.5 µM or 2 µM). Treated merozoites were then incubated with RBCs in 257 complete RPMI medium to allow invasion. Newly invaded ring-stage parasites were scored by flow 258 cytometry. Treatment of merozoites with peptide P1 and BV02 reduced the efficiency of erythrocyte 259 invasion in a dose-dependent manner (Fig. 6a ). Control peptides, P2 (without phosphorylation) and P3 260 (scrambled phosphopeptide) had no inhibitory effect on invasion.
261
The secretion of parasite invasion ligands from micronemes is a critical step in the invasion 262 process (2). Given that PfCDPK1 and PfPKAr have both been implicated in microneme secretion (4, 263 5), we examined if disruption of the high-molecular-weight multi-protein complex composed of 264 PfCDPK1, PfPKAr, and PKAc, can disrupt microneme secretion. Treatment of merozoites with peptide 265 P1 inhibited secretion of microneme protein PfAMA1, whereas control peptides P2 and P3 had no 266 effect ( Fig. 6b ). BV02 and peptides AA and RA also inhibit PfAMA1 discharge ( Fig. 6b ). Formation of 267 the Pf14-3-3I-mediated multi-protein complex, which includes PfCDPK1 and PfPKAr, thus appears to 268 be important for regulation of microneme secretion, a key step in the invasion process.
peptides from the label-free experiment were desalted with reverse-phase tC18 SepPak solid-phase 369 extraction cartridge 500mg (Waters) as described previously (31).
371
Ion-exchange fractionation of P. falciparum merozoite lysates. Fractionation of desalted peptides 372 was carried out with strong cation exchange (SCX) chromatography on a polySULFOETHYL-A 373 column as described before (31). 12-15 fractions of 4ml were collected, lyophilized till the volume was 374 reduced to 30% and desalted as described above. 
